Xilio Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
4. Property and Equipment, Net
Property and equipment, net consists of the following as of September 30, 2026 and December 31, 2025:
| September 30, · December 31, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Laboratory equipment | $ | 6,975 | $ | 6,381 |
| Furniture and fixtures | 681 | 681 | ||
| Leasehold improvements | 5,160 | 5,124 | ||
| Construction in process | — | 459 | ||
| Total property and equipment | 12,816 | 12,645 | ||
| Less: accumulated depreciation | (9,730) | (8,753) | ||
| Property and equipment, net | $ | 3,086 | $ | 3,892 |
The Company recognized depreciation and amortization expense related to property and equipment of$0.3 million and$0.3 million for the three months ended September 30, 2026 and 2025, respectively. The Company recognized depreciation and amortization expense related to property and equipment of$1.0 million and$1.2 million for the nine months ended September 30, 2026 and 2025, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.